TBP.TO

Tetra Bio-Pharma Inc. [TBP.TO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TBP.TO Stock Summary

In the News

TBP.TO Financial details

Company Rating
-
Market Cap
10.58M
Income
-39.37M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
03 Nov 2023
P/E
-0.21
Forward P/E
-
PEG
0.75
P/S
-
P/B
44.69
P/C
-
P/FCF
-0.4
Quick Ratio
0.7
Current Ratio
0.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.1
EPS next Y
-
EPS next Q
-
EPS this Y
20%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-7.61%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-707%
ROE
-468%
ROC
-99.63%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.015-0.075
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
-
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.29137
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
LLY.DE
FB2A.DE
EMBASSY.NS
META
AAPL
Same Sector
AKU
PTN
IONS
RANI
IMAC
Check Those
8027.HK
KAYS
HAFNI.OL
BBKP.JK
SKTP
Similar Market Cap
0ENN.L
8059.HK
JJA
HOYE.L
SADL

Company Profile

Healthcare Biotechnology
  • Market Capitalization 10.58M
  • Employee 33
  • CEO Dr. Guy Chamberland M.Sc., Master Herbal
  • Headquarters Orléans,ON,CA
  • IPO Date 2018-07-10
  • Website https://www.tetrabiopharma.com

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. The company is headquartered in Orléans, Canada.